At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 41 enrolled
Drug / intervention
Budesonide +1 moredrug
Likely dose
Budesonide 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of NasoNeb™ Delivery of an Intranasal Steroid in the Treatment of Perennial Allergic Rhinitis
In Brief
A Phase 4 clinical trial evaluating Budesonide and Placebo for Perennial Allergic Rhinitis. Completed, enrolled 41 participants across 1 site.
Detailed Summary
The purpose of this study is to see if a nasal steroid drug delivered to the nose with the NasoNeb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesUnited States
CollaboratorsMedInvent, LLC
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionJul 2012
Study CompletionAug 2012
TodayJul 2026
First PostedJan 5, 2011
Enrollment StartJan 1, 2011
Primary CompletionJul 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.5 years ago
Interventions
Budesonidedrug
Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
Placebodrug
Placebo delivered intranasally via NasoNeb nebulizer once daily